Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02810704 · ClinicalTrials.gov registry record · Phase 4
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 18,883
- Enrollment target
NCT02810704: Completed Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT02810704 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18,883 participants, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (3559% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02810704, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18,883 participants
- Enrollment target
Study Summary
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Primary Outcome
To compare the frequency of the aggregate primary clinical endpoints of important venous thromboembolism (clinical PE and DVT confirmed by imaging and leading to hospital readmission and/or therapeutic anticoagulation) and all-cause mortality (aggregate indicator of fatal events, including both PE and major hemorrhage related to anticoagulant use) among three different venous thromboembolism (VTE) prophylaxis regimens. An audit of all hospital readmissions within 6 months of operation will be ac
Interventions
- DRUG Warfarin
- DRUG Rivaroxaban
- DRUG Enteric Coated Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,883 participants |
| Start Date | 2016-12 |
| Est. Completion | 2025-09 |
| Phase | Phase 4 |
What the finished NCT02810704 record still lists
NCT02810704 is an interventional study that assigns participants to a tested intervention. Its 18,883 participants enrollment target places it among the larger protocols in the corpus, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (3559% higher).
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT02810704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02810704 about?
NCT02810704 is a clinical study titled "Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement". PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban...
What is the current status of trial NCT02810704?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18,883 participants. The study started on 2016-12. Estimated completion is 2025-09.
What interventions are being tested in trial NCT02810704?
The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (DRUG), Enteric Coated Aspirin (DRUG).
Who is sponsoring clinical trial NCT02810704?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02810704's enrollment target sits among peer trials
18,883 6th of 2000 higher than 1,995 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
- NCT05555095 · 19,331 participants
Examining Digital Health Care Delivery Models Through Medicaid Collaborative
- NCT07152249 · 19,480 participants · NA
Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia